Eveline Faes-van't Hull

Learn More
Tumor-mobilized bone marrow-derived CD11b(+) myeloid cells promote tumor angiogenesis, but how and when these cells acquire proangiogenic properties is not fully elucidated. Here, we show that CD11b(+) myelomonocytic cells develop proangiogenic properties during their differentiation from CD34(+) hematopoietic progenitors and that placenta growth factor(More)
Angiogenesis plays a key role in tumor growth and cancer progression. TIE-2-expressing monocytes (TEM) have been reported to critically account for tumor vascularization and growth in mouse tumor experimental models, but the molecular basis of their pro-angiogenic activity are largely unknown. Moreover, differences in the pro-angiogenic activity between(More)
Tumor-mobilized bone marrow–derived CD11b þ myeloid cells promote tumor angiogenesis, but how and when these cells acquire proangiogenic properties is not fully elucidated. Here, we show that CD11b þ myelomonocytic cells develop proangiogenic properties during their differentiation from CD34 þ hemato-poietic progenitors and that placenta growth factor(More)
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. ABSTRACT Tumor-mobilized bone marrow-derived CD11b + myeloid cells promote tumor angiogenesis, but how and when these cells acquire proangiogenic(More)
1. Division of Experimental Oncology, Centre Pluridiscipliniaire d’Oncologie (CePO), Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL). Faculty of Biology and Medicine, Lausanne, Switzerland; 2. National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole(More)
  • 1